MEMORIAL DAY FLASH SALE: 50% OFF BENZINGA PRO
As we honor our freedom, take a stand today. Secure the financial freedom that both you and your family deserve. Get exclusive market moving news for just 50% off. Claim your 50% discount here.
Alterity Therapeutics shares are trading higher on Tuesday after the company announced it received a development pathway from its meeting with the FDA for ATH434.
Alterity Therapeutics is active in the health care domain. The company is engaged in research collaboration with Takeda Pharmaceutical Co Ltd (NYSE:TAK) for the treatment of Parkinson's disease gastrointestinal neuropathology. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in pre-clinical toxicology testing.
Alterity Therapeutics shares were trading up 100.29% at $1.17 at the time of publication on Tuesday. The stock has a 52-week high of $1.63 and a 52-week low of 28 cents.
MEMORIAL DAY FLASH SALE: 50% OFF BENZINGA PRO
As we honor our freedom, take a stand today. Secure the financial freedom that both you and your family deserve. Get exclusive market moving news for just 50% off. Claim your 50% discount here.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!